Breaking News

Financial Report: PDL BioPharma

May 10, 2013

Royalty revenues up 19% in the quarter

PDL BioPharma

1Q Revenues: $91.8 million (+19%)

1Q Earnings: $53.5 million (+33%)

Comments: Royalty revenues were up 19% driven by increased royalties from Avastin, Herceptin, Lucentis, Tysabri, and Actemra.

blog comments powered by Disqus